Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)

NCT04794127 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT04794127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study on Trabectedin in Combination With PPARg Agonist Pioglitazone in Patients With Round Cell Myxoid Liposarcomas or Dedifferentiated G1 and G2 Liposarcomas With Stable Disease After a Monotherapy With Trabectedin. (TRABEPIO)
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2022
Completion date
September 23, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, dedifferentiated, liposarcoma, myxoid, liposarcoma, round cell